Nivolumab vs Osimertinib
Nivolumab vs Osimertinib: Overview
This comparison examines the pharmacological differences between Nivolumab and Osimertinib.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Osimertinib: Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.
Pharmacokinetics
Half-life: Nivolumab — 27 days; Osimertinib — 48 hours.
Chemical Properties
Molecular Formula: Osimertinib — C28H33N7O2.
Molecular Weight: Osimertinib — 499.6050 g/mol.
Type: Nivolumab — Antibody; Osimertinib — Small molecule.